Is There a Role for Using NMR Urine Metabolomics as a New Method of Screening for Colorectal Cancer?
This is a prospective, multi-centreed study to assess whether urine metabolomics can play a
role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000
patients going through an established CRC screening program, and from a further 500 patients
who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy,
the 1H NMR spectrum of urine samples will be analyzed for specific metabolites, and
establish the metabolomic signature of colorectal cancer. The results from metabolomic
urinalysis of this screening cohort will be compared with results from colonoscopy,
histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT)
to assess the accuracy of urine metabolomics in identifying patients with polyps and
malignancies. The urine metabolomic results from the colorectal cancer group will be
correlated with operative, histological and clinical staging to define the role of urine
metabolomics in assessing colorectal cancer type, location and stage. Additionally
approximately 300 urine samples from breast cancer patients and 300 from prostate cancer
patients will be collected to validate that the colorectal cancer signature is unique.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society